Home›Stock Screener›Indoco Remedies›Quarterly Results

Indoco Remedies Quarterly Results

Latest Quarter Net Profit
₹-24 Cr
QMar 2026
Quarterly Results

Indoco Remedies quarterly results. In Mar 2026, Indoco Remedies (INDOCO) reported revenue ₹460 Cr and net profit ₹-24 Cr — revenue +19.2% YoY. For annual financials, live price and key ratios, visit INDOCO screener.

INDOCO Quarterly Results — Revenue, Profit & EPS Highlights

Indoco Remedies latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Review INDOCO earnings multiple to evaluate earnings-based valuation against sector peers.

  • Revenue of ₹460 Cr in Mar 2026 (-18.7% vs Jun 2026, +19.2% vs Mar 2025)
  • Net Profit of ₹-24 Cr in Mar 2026 (-136.9% vs Jun 2026, +41.5% vs Mar 2025)
  • EBITDA of ₹34 Cr in Mar 2026 (-75.5% vs Jun 2026)
  • Operating Margin of 7.0% in Mar 2026 (-2.0pp vs Jun 2026)
  • Earnings Per Share of ₹-2.57 in Mar 2026 (-136.2% vs Jun 2026)

Indoco Remedies Quarterly Results — Revenue, EBITDA, Net Profit & EPS

INDOCO quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Mar 2026 Jun 2026 Sept 2025 Mar 2025 Jun 2025 QoQ YoY
Revenue (₹ Cr) 460 566 473 386 433 -18.7% 19.2%
Net Profit (₹ Cr) -24 65 -9 -41 -36 - -
EBITDA (₹ Cr) 34 139 30 -5 10 - -
EPS (₹) -2.57 7.09 -1.00 -4.48 -3.94 - -
Operating Margin (%) 7.0% 9.0% 6.0% -2.0% 2.0% - -

INDOCO Share Price Trend — 1-Year Movement Across Quarterly Results

Indoco Remedies 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Check INDOCO market cap trends to track the company's total market size over time.

Profitability Ratios

Profit Margin -5.2%
EBITDA Margin 7.4%
Operating Margin 7.0%
ROE (Annual) -10.3%

Balance Sheet Highlights

Total Assets ₹2,593 Cr
Total Equity ₹932 Cr
Current Assets ₹1,193 Cr
Current Liabilities ₹609 Cr

Cash Flow Analysis

Operating Cash Flow ₹192 Cr
Investing Cash Flow ₹-102 Cr
Financing Cash Flow ₹-77 Cr
Net Cash Flow ₹14 Cr

Current Market Data

Current Price ₹246.80
Exchange NSE
Last Updated Oct 05, 2026

Revenue Trend (₹ Cr)

Mar 2025 386
Sept 2025 473
Jun 2026 566
Mar 2026 460

Net Profit Trend (₹ Cr)

Mar 2025 -41
Sept 2025 -9
Jun 2026 65
Mar 2026 -24

Operating Margin Trend (%)

Mar 2025 -2.0%
Sept 2025 6.0%
Jun 2026 9.0%
Mar 2026 7.0%

INDOCO vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Indoco Remedies latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Mar 2026 		₹432,120.23 Cr 1779.7 15,018 2,710 -5.6% - 18.0% 157.5
Divis Laboratories
Mar 2026 		₹244,124.91 Cr 9196.0 2,986 751 -5.0% - 25.2% 324.8
Torrent Pharmaceuti…
Mar 2026 		₹188,719.51 Cr 4772.0 4,111 364 +27.7% +42.2% 8.9% 414.6
Zydus Life Science
Mar 2026 		₹113,615.69 Cr 1139.0 7,569 1,341 -4.3% - 17.7% 90.0
Cipla
Mar 2026 		₹108,576.18 Cr 1335.5 6,612 543 -9.3% - 8.2% 194.4
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data

QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores